Prescribing and Referral Resources: Aduhelm

Aduhelm Order Set

The order set serves as the prescription for treatment and facilitates proper prescribing by capturing the necessary elements of a valid, complete infusion order.

  • Captures criteria for indicated use per FDA-approved labeling
  • Guides the infusion clinician in safe administration by prompting best practices and adherence to administration requirements
  • Supports continuity of care by prompting the infusion provider to send records of completed treatment to the prescriber
Aduhelm Indications Checklist

This checklist is intended to help prescribers determine if treatment with Aduhelm is indicated in accordance with the FDA-approved labeling.

  • If Aduhelm is not indicated, the checklist can be included in the medical record to document the clinical decision-making process
  • If Aduhelm is indicated, the checklist can accompany the medication order set to document eligibility criteria and support medical necessity*

*Individual infusion site documentation requirements may vary.

Aduhelm Referral Checklist

Many HCPs prescribing aducanumab may be unfamiliar with the infusion referral process. This template checklist provides an overview of necessary steps to refer a patient for aducanumab therapy in order to streamline the referral process to reduce unnecessary delays and expedite access to treatment. Infusion sites of care are encouraged to download and modify this checklist to create a custom checklist including any unique, site-specific requirements.**

**If materials/content are modified in any way, the NICA logo must be removed.

Aduhelm Patient and Caregiver Discharge Instructions

This patient handout explains signs and symptoms to watch for and report following an Aduhelm infusion.

  • Provides home care instructions for discomfort at the IV site
  • Reinforces education regarding signs/symptoms which could be suggestive of amyloid-related imaging abnormalities (ARIA) and therefore necessitate urgent medical attention.
Patient Education_Preparing for Your Infusion

Prescribers can provide and review this handout with patients to help them understand and prepare for their infusion to promote treatment acceptance and adherence.

  • Includes a field for the prescriber to indicate facility name and phone number where referral/order was sent, with instructions for the patient to call if they have not received an appointment. This is intended to reduce treatment delays or confusion due to communication challenges.
Aduhelm Evaluation Orders

Prior to prescribing Aduhelm, healthcare providers must first confirm the presence of amyloid-beta (Aβ) pathology via cerebrospinal fluid (CSF) assessment or Amyloid PET scan. Patients must also have a baseline brain MRI prior to initiation of therapy, as well as repeat MRIs prior to the 7th and 12th doses to evaluate for amyloid-related imaging abnormalities (ARIA). This template order set guides the healthcare provider in ordering the correct tests to evaluate and monitor current or potential Aduhelm patients.

Aduhelm Website

Additional Resources

Aduhelm Full Prescribing Information

Aduhelm Patient Medication Guide

Prescribers should review the patient medication guide with the patient/caregiver when the treatment decision is made. Per NICA Minimum Standards for In-Office Infusion, infusion providers should also provide the patient/caregiver with a copy of the Patient Medication Guide prior to their first treatment.

Cognitive Assessment Toolkit

Detecting possible cognitive impairment is the first step in determining whether or not a patient needs further evaluation. The Alzheimer’s Association developed the Cognitive Assessment Toolkit. According to the Alzheimer’s Association, individuals whose cognitive assessments indicate that their memory or cognition is consistent with MCI or early Alzheimer’s dementia should be evaluated further or referred to a specialist.

Medicare Annual Wellness Visit Algorithm for Assessment of Cognition

The Alzheimer’s Association convened a group of practicing expert clinicians to make consensus recommendations for an effective, practical, and easy process for detecting cognitive impairment in the primary care setting. The group identified several brief tools to evaluate cognition, all of which can be administered in five minutes or less by a physician or other trained staff. The resulting algorithm (PDF) incorporates patient history, clinician observations, and concerns expressed by the patient, family or caregiver.

Aducanumab Resources for Clinicians

The Alzheimer’s Association website contains a wealth of valuable information for health systems and clinicians about Aduhelm.

Log in with your credentials

or    

Forgot your details?

Create Account